Typically measured during first-trimester assessments at 11‒13 weeks, lower levels of PAPP-A have been linked with a high risk of adverse fetal complications, especially preterm birth, as well as increased incidence of maternal hypertensive disorders such as preeclampsia during pregnancy.61 The gene discussed is PAPPA; the disease is hypertensive disorder.